BioSpace News Archive

MEI Pharma, Inc. announced that pursuant to the previously disclosed cooperation agreement with Anson Funds and Cable Car Capital, the Company’s Board of Directors today declared a special cash dividend of $1.75 per share of common stock, $0.00000002 par value, payable on December 6, 2023 to stockholders of record at the close of business on November 17, 2023.

Gilead Sciences, Inc. and Arcus Biosciences, Inc. announced that domvanalimab plus zimberelimab and chemotherapy showed encouraging overall response rate and six-month progression-free survival rate results in a preliminary analysis from Arm A1 of the EDGE-Gastric study.

Puma Biotechnology, Inc., a biopharmaceutical company, announced that on November 1, 2023, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering 15,000 shares of Puma common stock to one new non-executive employee.

Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the three months ended September 30, 2023.

Aquestive Therapeutics, Inc. (NASDAQ:AQST) today reported financial results for the third quarter ended September 30, 2023 and provided an update on recent developments in its business.

Clover Biopharmaceuticals, Ltd. announced the company completes the Biologic License Application submission for its seasonal influenza vaccine to Brazilian Health Regulatory Agency.

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), today announced data presentations highlighting additional analyses from the Phase 3 NefIgArd study with Nefecon in adults with primary IgA nephropathy (IgAN), as well as pre-clinical data on the treatment of Alport syndrome with setanaxib, a novel NOX inhibitor, presented at the American Society of Nephrology (ASN) Kidney Week 2023 in Philadelphia, PA on November 1-5, 2023.

Alpine Immune Sciences, Inc. (Nasdaq: ALPN) today announced the pricing of its underwritten public offering of 8,800,000 shares of its common stock and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase up to 3,200,000 shares of its common stock, pursuant to its existing shelf registration statement.

Aura Biosciences, Inc. announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $9.00 per share.